On Dec. 22, 2020, a phase II clinical trial of a treatment for COVID-19 patients was started at the Medical University of Vienna as a sub-study of the Austrian CoronaVirus Adaptive Clinical Trial (ACOVACT). The trial was initiated as an academia-industry collaboration (investigator Initiated trial) between Apogenix, a biotech company based in Heidelberg, and the University of Cologne and University College London.